Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10 september 2016 uppdaterad av: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

991

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Bosnien och Hercegovina
      • Banja Luka, Bosnien och Hercegovina, 78000
      • Sarajewo, Bosnien och Hercegovina, 71000
  • Brasilien
      • Belo Horizonte, Brasilien, 30150-281
      • Curitiba, Brasilien, 80530-010
      • Goiania, Brasilien, 74605-070
      • Itajai, Brasilien, 88301-220
      • JAU, Brasilien, 17210-080
      • Joao Pessoa, Brasilien, 58040280
      • Porto Alegre, Brasilien, 90610-000
      • Porto Alegre, Brasilien, 91350-200
      • Porto Alegre, Brasilien, 90430-090
      • Porto Alegre - Rs, Brasilien, 90050-170
      • Rio de Janeiro, Brasilien, 20560-120
      • Rio de Janeiro, Brasilien, 22260-020
      • Santo Andre, Brasilien, 09060-870
      • Sao Paulo, Brasilien, 1323020
      • Sao Paulo, Brasilien, 01317-000
  • Bulgarien
      • Plovdiv, Bulgarien, 4000
      • Sofia, Bulgarien, 1756
      • Sofia, Bulgarien, 1784
      • Varna, Bulgarien, 9002
  • Colombia
      • Bogota, Colombia
      • Bogota, Colombia, 49 00
      • Monteria, Colombia
  • Danmark
      • Herlev, Danmark, 2730
      • København, Danmark, 2100
      • Odense, Danmark, 5000
  • Filippinerna
      • Diliman, Quezon City, Filippinerna, 1100
      • Quezon City, Luzon, Filippinerna, 1101
  • Finland
      • Helsinki, Finland, 00180
      • Tampere, Finland, 33520
      • Turku, Finland, 20520
  • Frankrike
      • Avignon, Frankrike, 84082
      • Bordeaux, Frankrike, 33076
      • Brest, Frankrike, 29609
      • Caen, Frankrike, 14076
      • Dijon, Frankrike, 21079
      • La Roche Sur Yon, Frankrike, 85925
      • Montpellier, Frankrike, 34298
      • Paris, Frankrike, 75248
      • Saint Brieuc, Frankrike, 22015
      • Saint Herblain, Frankrike, 44805
      • Vandoeuvre-les-nancy, Frankrike, 54511
  • Förenta staterna
    • Arizona
      • Chandler, Arizona, Förenta staterna, 85224
      • Tucson, Arizona, Förenta staterna, 85719
    • California
      • Anaheim, California, Förenta staterna, 92801
      • Anaheim, California, Förenta staterna, 92807
      • Bakersfield, California, Förenta staterna, 93309
      • Baldwin Park, California, Förenta staterna, 91706
      • Bellflower, California, Förenta staterna, 90706
      • Duarte, California, Förenta staterna, 91010
      • Fontana, California, Förenta staterna, 92335
      • Hayward, California, Förenta staterna, 94545
      • Irvine, California, Förenta staterna, 92618
      • La Jolla, California, Förenta staterna, 92093
      • La Mesa, California, Förenta staterna, 91942
      • Loma Linda, California, Förenta staterna, 92354
      • Long Beach, California, Förenta staterna, 90806
      • Los Angeles, California, Förenta staterna, 90025
      • Los Angeles, California, Förenta staterna, 90057
      • Los Angeles, California, Förenta staterna, 90095-1772
      • Los Angeles, California, Förenta staterna, 90034
      • Montebello, California, Förenta staterna, 90640
      • Newport Beach, California, Förenta staterna, 92660
      • Oakland, California, Förenta staterna, 94611
      • Panorama City, California, Förenta staterna, 91402
      • Riverside, California, Förenta staterna, 92505
      • Roseville, California, Förenta staterna, 95661
      • Sacramento, California, Förenta staterna, 95825
      • San Diego, California, Förenta staterna, 92123
      • San Diego, California, Förenta staterna, 92120
      • San Francisco, California, Förenta staterna, 94115
      • San Jose, California, Förenta staterna, 95119
      • Santa Clara, California, Förenta staterna, 95051
      • Santa Maria, California, Förenta staterna, 93454
      • Santa Monica, California, Förenta staterna, 90404
      • South San Francisco, California, Förenta staterna, 94080
      • Thousand Oaks, California, Förenta staterna, 91360
      • Vallejo, California, Förenta staterna, 94589
      • Walnut Creek, California, Förenta staterna, 94596
      • Woodland Hills, California, Förenta staterna, 91367
    • Colorado
      • Fort Collins, Colorado, Förenta staterna, 80528
    • Connecticut
      • Norwalk, Connecticut, Förenta staterna, 06856
      • Norwich, Connecticut, Förenta staterna, 06360
      • Stamford, Connecticut, Förenta staterna, 06902
    • District of Columbia
      • Washington, District of Columbia, Förenta staterna, 20010
    • Florida
      • Boca Raton, Florida, Förenta staterna, 33486
      • Fernandina Beach, Florida, Förenta staterna, 32034
      • Fort Myers, Florida, Förenta staterna, 33916
      • Ft. Lauderdale, Florida, Förenta staterna, 33316
      • Hollywood, Florida, Förenta staterna, 33021
      • Jacksonville, Florida, Förenta staterna, 32205
      • Jacksonville, Florida, Förenta staterna, 32256
      • Jacksonville, Florida, Förenta staterna, 32207
      • Jacksonville, Florida, Förenta staterna, 32258
      • Kissimmee, Florida, Förenta staterna, 34741
      • Lakeland, Florida, Förenta staterna, 33804-1057
      • Miami, Florida, Förenta staterna, 33136
      • Miami, Florida, Förenta staterna, 33176
      • Miami, Florida, Förenta staterna, 33133
      • Orange Park, Florida, Förenta staterna, 32073
      • Pembroke Pines, Florida, Förenta staterna, 33028
    • Georgia
      • Athens, Georgia, Förenta staterna, 30607
      • Atlanta, Georgia, Förenta staterna, 30342
      • Atlanta, Georgia, Förenta staterna, 30322
      • Atlanta, Georgia, Förenta staterna, 30341
      • Atlanta, Georgia, Förenta staterna, 30318
      • Carrolton, Georgia, Förenta staterna, 30117
      • Cartersville, Georgia, Förenta staterna, 30121
      • Decatur, Georgia, Förenta staterna, 30033
      • Douglasville, Georgia, Förenta staterna, 30134
      • Macon, Georgia, Förenta staterna, 31217
      • Marietta, Georgia, Förenta staterna, 30060
    • Idaho
      • Boise, Idaho, Förenta staterna, 83712
      • Meridian, Idaho, Förenta staterna, 83642
      • Nampa, Idaho, Förenta staterna, 83686
      • Post Falls, Idaho, Förenta staterna, 83854
      • Twin Falls, Idaho, Förenta staterna, 83301
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60612
      • Decatur, Illinois, Förenta staterna, 62526
      • Effingham, Illinois, Förenta staterna, 62526
      • Joliet, Illinois, Förenta staterna, 60435
      • Morris, Illinois, Förenta staterna, 60450
      • Peoria, Illinois, Förenta staterna, 61615-7828
      • Skokie, Illinois, Förenta staterna, 60076
      • Zion, Illinois, Förenta staterna, 60099
    • Iowa
      • Bettendorf, Iowa, Förenta staterna, 52722
    • Kansas
      • Wichita, Kansas, Förenta staterna, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Förenta staterna, 42001
    • Louisiana
      • Covington, Louisiana, Förenta staterna, 70433
      • Lafayette, Louisiana, Förenta staterna, 70503
      • Marrero, Louisiana, Förenta staterna, 70072
      • Metairie, Louisiana, Förenta staterna, 70006
      • New Orleans, Louisiana, Förenta staterna, 70115
    • Maine
      • Kittery, Maine, Förenta staterna, 03904
      • Wells, Maine, Förenta staterna, 04090
      • York, Maine, Förenta staterna, 03909
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21202
      • Baltimore, Maryland, Förenta staterna, 21237
      • Bethesda, Maryland, Förenta staterna, 20817
      • Rockville, Maryland, Förenta staterna, 20850
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02215
      • Boston, Massachusetts, Förenta staterna, 02114
      • Boston, Massachusetts, Förenta staterna, 02118
      • Boston, Massachusetts, Förenta staterna, 02115
      • Burlington, Massachusetts, Förenta staterna, 01805
      • Peabody, Massachusetts, Förenta staterna, 01960
    • Michigan
      • Brownstown, Michigan, Förenta staterna, 48183
      • Dearborn, Michigan, Förenta staterna, 48126
      • Detroit, Michigan, Förenta staterna, 48201
      • Detroit, Michigan, Förenta staterna, 48202
      • Saint Joseph, Michigan, Förenta staterna, 49085
      • West Bloomfield, Michigan, Förenta staterna, 48322
    • Minnesota
      • Edina, Minnesota, Förenta staterna, 55414
      • Maplewood, Minnesota, Förenta staterna, 55109
      • Minneapolis, Minnesota, Förenta staterna, 55454
      • Saint Louis Park, Minnesota, Förenta staterna, 55426
      • Saint Paul, Minnesota, Förenta staterna, 55101
      • St. Louis Park, Minnesota, Förenta staterna, 55426
    • Missouri
      • Joplin, Missouri, Förenta staterna, 64804
      • Kansas City, Missouri, Förenta staterna, 64111
      • Saint Louis, Missouri, Förenta staterna, 63110
      • Saint Peters, Missouri, Förenta staterna, 63110
      • St. Louis, Missouri, Förenta staterna, 63141
      • St. Peters, Missouri, Förenta staterna, 63376
    • Montana
      • Missoula, Montana, Förenta staterna, 59802
    • Nebraska
      • Omaha, Nebraska, Förenta staterna, 68114
    • Nevada
      • Henderson, Nevada, Förenta staterna, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Förenta staterna, 08002
      • Hackensack, New Jersey, Förenta staterna, 07601
      • Morristown, New Jersey, Förenta staterna, 07962
      • Parsippany, New Jersey, Förenta staterna, 07054
      • Voorhees, New Jersey, Förenta staterna, 08043
    • New Mexico
      • Santa Fe, New Mexico, Förenta staterna, 87505
    • New York
      • Brockport, New York, Förenta staterna, 14420
      • Canandaigua, New York, Förenta staterna, 14424
      • Fresh Meadows, New York, Förenta staterna, 11366
      • Geneva, New York, Förenta staterna, 14456
      • Greece, New York, Förenta staterna, 14626
      • Lake Success, New York, Förenta staterna, 11042
      • Mount Kisco, New York, Förenta staterna, 10549
      • Rochester, New York, Förenta staterna, 14626
      • Stony Brook, New York, Förenta staterna, 11794
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28203
      • Durham, North Carolina, Förenta staterna, 27710
      • Hickory, North Carolina, Förenta staterna, 28602
      • Kinston, North Carolina, Förenta staterna, 28501
      • Washington, North Carolina, Förenta staterna, 27889
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44195
      • Cleveland, Ohio, Förenta staterna, 44106
      • Columbus, Ohio, Förenta staterna, 43215
      • Columbus, Ohio, Förenta staterna, 43219
      • Columbus, Ohio, Förenta staterna, 43228
      • Middletown, Ohio, Förenta staterna, 45042
      • Newark, Ohio, Förenta staterna, 43055
      • Sandusky, Ohio, Förenta staterna, 44870
    • Oregon
      • Portland, Oregon, Förenta staterna, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19124
      • Philadelphia, Pennsylvania, Förenta staterna, 19106
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
    • Rhode Island
      • East Providence, Rhode Island, Förenta staterna, 02915
    • South Carolina
      • Columbia, South Carolina, Förenta staterna, 29210
      • North Charleston, South Carolina, Förenta staterna, 29425
    • Tennessee
      • Memphis, Tennessee, Förenta staterna, 38120
      • Nashville, Tennessee, Förenta staterna, 37203
    • Texas
      • Austin, Texas, Förenta staterna, 78731
      • Bryan, Texas, Förenta staterna, 77802
      • Cypress, Texas, Förenta staterna, 77429
      • Dallas, Texas, Förenta staterna, 75230
      • El Paso, Texas, Förenta staterna, 79902
      • Houston, Texas, Förenta staterna, 77090
      • Shenandoah, Texas, Förenta staterna, 77384
      • Temple, Texas, Förenta staterna, 76501
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
    • Washington
      • Gig Harbor, Washington, Förenta staterna, 98332
      • Lakewood, Washington, Förenta staterna, 98499
      • Puyallup, Washington, Förenta staterna, 98372
      • Tacoma, Washington, Förenta staterna, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Förenta staterna, 53226
      • Wausau, Wisconsin, Förenta staterna, 54401
  • Hong Kong
      • Hong Kong, Hong Kong
  • Indien
      • Bangalore, Indien, 560027
      • Gurgaon, Indien, 122001
      • Kolkata, Indien, 700 053
      • New Delhi, Indien, 110029
      • Pune, Indien, 411004
  • Italien
      • Aviano, Italien, 33081
      • Bologna, Italien, 40138
      • Candiolo, Italien, 10060
      • Genova, Italien, 16132
      • Meldola, Italien, 47014
      • Milano, Italien, 20133
      • Milano, Italien, 20141
      • Napoli, Italien, 80131
      • Negrar, Italien, 37024
      • Pisa, Italien, 56100
      • Reggio Emilia, Italien, 42100
      • Roma, Italien, 00168
      • Rozzano, Italien, 20089
      • Sassari, Italien, 07100
      • Terni, Italien, 05100
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
      • Edmonton, Alberta, Kanada, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 5L3
      • Vancouver, British Columbia, Kanada, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
      • Sudbury, Ontario, Kanada, J9P 3Y1
      • Toronto, Ontario, Kanada, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Kanada, J4V 2H1
      • Montreal, Quebec, Kanada, H1T 2M4
      • Montreal, Quebec, Kanada, H3T 1E2
      • Montreal, Quebec, Kanada, H2W 1T8
  • Korea, Republiken av
      • Kyunggi-do, Korea, Republiken av, 411-769
      • Seoul, Korea, Republiken av, 110-744
      • Seoul, Korea, Republiken av, 120-752
      • Seoul, Korea, Republiken av, 135-710
  • Mexiko
      • Acapulco, Mexiko, 39670
      • Oaxaca, Mexiko, 68000
      • Toluca, Mexiko, 50180
  • Nya Zeeland
      • Newtown, Nya Zeeland, 6021
      • Palmerston North, Nya Zeeland, 4442
  • Polen
      • Bialystok, Polen, 15-027
      • Gdansk, Polen, 80-952
      • Krakow, Polen, 31-531
      • Lublin, Polen, 20-090
      • Opole, Polen, 45-060
      • Poznan, Polen, 61-866
      • Warszawa, Polen, 02-781
  • Portugal
      • Coimbra, Portugal, 3000-075
      • Lisboa, Portugal, 1649-035
      • Porto, Portugal, 4200-072
  • Ryska Federationen
      • Kemerovo, Ryska Federationen, 650036
      • Moscow, Ryska Federationen, 121356
      • St Petersburg, Ryska Federationen, 197758
  • Schweiz
      • Luzern, Schweiz, 6004
      • St. Gallen, Schweiz, 9007
  • Singapore
      • Singapore, Singapore, 119074
      • Singapore, Singapore, 169610
  • Slovenien
      • Ljubljana, Slovenien, 1000
  • Spanien
      • Barcelona, Spanien, 08035
      • Córdoba, Spanien, 14004
      • Lerida, Spanien, 25198
      • Madrid, Spanien, 28046
      • Madrid, Spanien, 28041
      • Santander, Spanien, 39008
      • Sevilla, Spanien, 41013
      • Valencia, Spanien, 46009
      • Zaragoza, Spanien, 50009
  • Storbritannien
      • Bournemouth, Storbritannien, BH7 7DW
      • Cardiff, Storbritannien, CF14 2TL
      • Denbigh, Storbritannien, LL18 5UJ
      • London, Storbritannien, SE1 7EH
      • London, Storbritannien, SW3 6JJ
      • Manchester, Storbritannien, M20 4BX
      • New Castle Upon Tyne, Storbritannien, NE7 7DN
      • Northwood, Storbritannien, HA6 2RN
      • Poole, Storbritannien, BH15 2JB
      • Preston, Storbritannien, PR2 9HT
      • Romford, Storbritannien, RM7 0AG
      • Sutton, Storbritannien, SM2 5PT
      • Weston Super Mare, Storbritannien, BS23 4TQ
  • Sverige
      • Eskilstuna, Sverige, 63188
      • Gaelve, Sverige, 80187
      • Goteborg, Sverige, 40036
  • Taiwan
      • Kaohsung, Taiwan, 883
      • Taichung, Taiwan, 404
      • Taichung, Taiwan, 407
      • Taipei, Taiwan, 112
      • Taoyuan, Taiwan, 333
  • Tyskland
      • Aschaffenburg, Tyskland, 63739
      • Berlin, Tyskland, 10367
      • Berlin, Tyskland, 13125
      • Berlin, Tyskland, 4169
      • Bonn, Tyskland, 53113
      • Dortmund, Tyskland, 44137
      • Freiburg, Tyskland, 79106
      • Fuerstenwalde, Tyskland, 15517
      • Hamburg, Tyskland, 20357
      • Karlsruhe, Tyskland, 76135
      • Kiel, Tyskland, 24105
      • Offenbach, Tyskland, 63069
      • Stralsund, Tyskland, 18435

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Läkemedel: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Andra namn:
  • RO5304020
  • T-DM1
  • Trastuzumab-MCC-DM1
Aktiv komparator: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Läkemedel: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Andra namn:
  • Tykerb
  • Tyverb
Läkemedel: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Andra namn:
  • Xeloda

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Tidsram: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Tidsram: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Tidsram: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Tidsram: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Tidsram: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Tidsram: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants With PD or Death as Assessed by the Investigator
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Tidsram: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Hoffmann-La Roche

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 februari 2009

Primärt slutförande (Faktisk)

1 juli 2012

Avslutad studie (Faktisk)

1 september 2015

Studieregistreringsdatum

Först inskickad

22 januari 2009

Först inskickad som uppfyllde QC-kriterierna

22 januari 2009

Första postat (Uppskatta)

26 januari 2009

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

31 oktober 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 september 2016

Senast verifierad

1 september 2016

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • BO21977
  • TDM4370g (Annan identifierare: Genentech)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Bröstcancer

Kliniska prövningar på Trastuzumab emtansine

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Kosovo

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera